Short answer
Monopar Therapeutics (MNPR) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 with net income of −$3M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- Net income
- −$3M
- −163.6% YoY · −40.1% QoQ
- EPS (diluted)
- −$0.48
- +58.6% YoY · −37.1% QoQ
Source: XBRL data from the Monopar Therapeutics (MNPR) Q3 2025 10-Q on SEC EDGAR. USD.
Monopar Therapeutics Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no approved drugs or operating revenue
- Net loss $3.438M vs $1.304M YoY; operating loss $4.093M vs $1.575M
- R&D expenses $2.590M vs $0.984M, driven by ALXN1840 manufacturing and personnel costs
- Cash, equivalents and investments $143.7M at September 30, 2025; operating cash use $8.831M vs $4.406M
- September financing generated $91.9M net proceeds after $35M share repurchase; funds expected through December 31, 2027
Risk Factors
- No risk-factors section provided in the submitted excerpt
- September 2025 underwriting agreement and pre-funded warrants indicate financing-related activity
- Share Purchase Agreement with Tactic Pharma, LLC dated September 24, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Monopar Therapeutics quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.